Illumina, Inc. vs GraniteShares 2x Long NVDA Daily ETF — how do they compare? Illumina, Inc. trades at $180.13 (market cap $27.94B), while GraniteShares 2x Long NVDA Daily ETF trades at $31.19. The key difference: Illumina, Inc. is trading nearer its 52-week high, GraniteShares 2x Long NVDA Daily ETF nearer its low. Which is the better fit depends on your goals.
| ILMN | NVDL | |
|---|---|---|
Market Cap | $27.94B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $194.33 | $43.02 |
52-Week Low | $91.00 | $21.76 |
Enterprise Value | $29.33B | — |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $30.51 with a 0.76% daily gain. The technical outlook is bearish with moving averages signaling selling pressure, while oscillators remain neutral. Recent news highlights the fund's volatility, including a 12% single-day drop on June 5, 2026, and a 67% decline in early 2025, underscoring the risks of daily leverage reset mechanics.
The outlook for NVDL is heavily tied to NVIDIA's performance and AI sector momentum. While the ETF has delivered strong returns year-to-date (up 12.66% as of June 8, 2026), its leveraged structure amplifies both gains and losses. Key risks include NVIDIA's earnings volatility, broader semiconductor market swings, and the compounding effect of daily resets during downtrends.
Trailing returns across standard periods
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →